American Society of Hirudotherapy

Cysteine-Rich Anticoagulant (CRA)

Novel cysteine-rich recombinant anticoagulant from Hirudo medicinalis saliva — strong anticoagulant activity in clotting assays; C-terminal motif governs membrane affinity.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 27, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Cysteine-Rich Anticoagulant (CRA)12 kDa
Molecular weight (kilodaltons) of Cysteine-Rich Anticoagulant (CRA) (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Recombinant (genetically expressed)
Safety domains
Bleeding

Clinical translation limit

CRA's in vitro anticoagulant activity (3.7-5.5 mg/L recombinant yield, retained clotting-assay activity) does NOT establish clinical efficacy of any whole-leech or recombinant therapy. No FDA-approved CRA derivative exists; characterization remains at scale-up / purification stage.

Molecular Profile

Category
Anticoagulant
Evidence tier
Preclinical
Molecular weight
12,000 Da
Source species
Hirudo medicinalis
Discovered
2025 · Manuvera VA et al.

Biological Targets

  • → coagulation cascade (TT / PT / aPTT prolongation; membrane-associated mechanism)

Key Citations

  1. Manuvera VA et al. (2025), Biomolecules · PMID 41463289

External Resources

    Related Anticoagulant Compounds

    This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.